3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-646e1fce9b8930c4.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"Image"]
9:I[4019,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-646e1fce9b8930c4.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"default"]
2:T5cd,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does ATX do?","acceptedAnswer":{"@type":"Answer","text":"Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing small molecule inhibitors for Focal Adhesion Kinase (FAK) and p38 MAPK. Their primary drug candidates, AMP945 and AMP880, are being investigated for the treatment of various cancers (like pancreatic cancer) and fibrotic diseases (such as idiopathic pulmonary fibrosis)."}},{"@type":"Question","name":"Is ATX a good investment?","acceptedAnswer":{"@type":"Answer","text":"Investing in ATX is highly speculative, characteristic of micro-cap biotechnology companies on the ASX. Its potential for significant returns is directly linked to successful clinical trial outcomes and eventual commercialisation of its drug candidates, but it carries substantial risks, including trial failures, funding challenges, and intense competitive pressures in the biopharmaceutical sector."}},{"@type":"Question","name":"What drives ATX's share price?","acceptedAnswer":{"@type":"Answer","text":"The share price of ATX is primarily driven by announcements related to its clinical trial progress, particularly positive or negative data readouts for AMP945 and AMP880, regulatory milestones (e.g., approvals for trial progression), securing new funding, and potential partnership or licensing agreements with larger pharmaceutical companies."}}]}6:["ticker","ATX","d"]
0:["eCy3-J0ZIPs_GGnvutRNr",[[["",{"children":["asx",{"children":[["ticker","ATX","d"],{"children":["__PAGE__?{\"ticker\":\"ATX\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","ATX","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Amplia Therapeutics Limited"," (","ATX",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing novel treatments for cancer and fibrosis. The company is advancing small molecule inhibitors, including AMP945 (a FAK inhibitor) and AMP880 (a p38 MAPK inhibitor), with lead programs targeting pancreatic cancer and idiopathic pulmonary fibrosis."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$64M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"ATX"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Amplia Therapeutics is a clinical-stage biotechnology firm with a market capitalisation of A$67 million, positioning it as a highly speculative investment primarily driven by its drug development pipeline. Its lead candidate, AMP945, a Focal Adhesion Kinase (FAK) inhibitor, is currently in Phase 1 and Phase 2 clinical trials for challenging indications like pancreatic cancer and idiopathic pulmonary fibrosis (IPF), which represent significant unmet medical needs. As a pre-revenue company, its financial performance is characterised by R&D expenditure, with value creation entirely dependent on successful clinical outcomes and future commercialisation.",{"children":"Amplia Therapeutics is a clinical-stage biotechnology firm with a market capitalisation of A$67 million, positioning it as a highly speculative investment primarily driven by its drug development pipeline. Its lead candidate, AMP945, a Focal Adhesion Kinase (FAK) inhibitor, is currently in Phase 1 and Phase 2 clinical trials for challenging indications like pancreatic cancer and idiopathic pulmonary fibrosis (IPF), which represent significant unmet medical needs. As a pre-revenue company, its financial performance is characterised by R&D expenditure, with value creation entirely dependent on successful clinical outcomes and future commercialisation."}],["$","p","The growth outlook for Amplia is intrinsically tied to the progression and success of its clinical trials for AMP945 and AMP880. Key catalysts include upcoming data readouts from its ongoing Phase 2 pancreatic cancer trial and further advancement in its IPF program, which could validate its therapeutic approach and attract potential pharmaceutical partners. The strategic direction involves advancing these compounds through later-stage clinical development, seeking regulatory approvals, and exploring out-licensing or collaboration opportunities to fund commercialisation, given its small market capitalisation.",{"children":"The growth outlook for Amplia is intrinsically tied to the progression and success of its clinical trials for AMP945 and AMP880. Key catalysts include upcoming data readouts from its ongoing Phase 2 pancreatic cancer trial and further advancement in its IPF program, which could validate its therapeutic approach and attract potential pharmaceutical partners. The strategic direction involves advancing these compounds through later-stage clinical development, seeking regulatory approvals, and exploring out-licensing or collaboration opportunities to fund commercialisation, given its small market capitalisation."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Positive Phase 2 clinical trial results for AMP945 in pancreatic cancer or idiopathic pulmonary fibrosis, demonstrating significant efficacy and safety that de-risks future development.",{"children":["â€¢ ","Positive Phase 2 clinical trial results for AMP945 in pancreatic cancer or idiopathic pulmonary fibrosis, demonstrating significant efficacy and safety that de-risks future development."]}],["$","li","Securing a lucrative licensing agreement or strategic partnership with a major pharmaceutical company for one or more of its drug candidates, providing significant non-dilutive funding and market access.",{"children":["â€¢ ","Securing a lucrative licensing agreement or strategic partnership with a major pharmaceutical company for one or more of its drug candidates, providing significant non-dilutive funding and market access."]}],["$","li","Successful expansion of clinical programs into additional high-value indications, broadening the market opportunity and potential revenue streams for its pipeline.",{"children":["â€¢ ","Successful expansion of clinical programs into additional high-value indications, broadening the market opportunity and potential revenue streams for its pipeline."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Unfavourable or inconclusive results from ongoing or future clinical trials, leading to program delays, termination, or significant re-evaluation of its drug candidates.",{"children":["â€¢ ","Unfavourable or inconclusive results from ongoing or future clinical trials, leading to program delays, termination, or significant re-evaluation of its drug candidates."]}],["$","li","Inability to secure sufficient funding for continued R&D and clinical development without significant shareholder dilution, impacting its ability to progress trials.",{"children":["â€¢ ","Inability to secure sufficient funding for continued R&D and clinical development without significant shareholder dilution, impacting its ability to progress trials."]}],["$","li","Intense competition from larger pharmaceutical companies developing similar or superior treatments for pancreatic cancer or IPF, potentially limiting future market share.",{"children":["â€¢ ","Intense competition from larger pharmaceutical companies developing similar or superior treatments for pancreatic cancer or IPF, potentially limiting future market share."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Market Sentiment"}],["$","div",null,{"className":"mt-4 flex items-center gap-3","children":[["$","span",null,{"className":"inline-flex items-center gap-1.5 rounded-full border px-3 py-1 text-sm font-semibold bg-yellow-500/10 border-yellow-500/30 text-yellow-400","children":["ðŸŸ¡"," ","Mixed"]}],["$","span",null,{"className":"text-xs text-slate-500","children":["Score: ","","0.00"]}]]}],["$","div",null,{"className":"mt-4","children":[["$","div",null,{"className":"flex justify-between text-[10px] uppercase tracking-widest text-slate-500","children":[["$","span",null,{"children":"Bearish"}],["$","span",null,{"children":"Bullish"}]]}],["$","div",null,{"className":"relative mt-1 h-2 rounded-full bg-ink-900/60","children":[["$","div",null,{"className":"absolute left-1/2 top-0 h-full w-px bg-slate-600"}],["$","div",null,{"className":"absolute top-0 h-full w-2 rounded-full bg-yellow-500","style":{"left":"calc(50% - 4px)"}}]]}]]}],["$","div",null,{"className":"mt-4 flex gap-4 text-xs","children":[["$","span",null,{"className":"text-emerald-400","children":["â–² ",0," bullish"]}],["$","span",null,{"className":"text-red-400","children":["â–¼ ",0," bearish"]}],["$","span",null,{"className":"text-slate-500","children":[23," neutral"]}]]}],["$","p",null,{"className":"mt-1 text-xs text-slate-500","children":["Based on ",23," social post","s"]}],["$","div",null,{"className":"mt-4 space-y-2","children":[["$","p",null,{"className":"text-xs uppercase tracking-widest text-slate-500","children":"Recent mentions"}],[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-06"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Amplia Therapeutics Limited"}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-06"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Amplia Therapeutics Limited"}]]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-3 text-xs","children":[["$","div",null,{"className":"flex items-center gap-2","children":[["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5 text-[10px] text-slate-400","children":"hotcopper"}],["$","span",null,{"className":"text-slate-500","children":"2026-02-06"}],["$","span",null,{"className":"text-slate-400","children":"â€”"}]]}],["$","p",null,{"className":"mt-1.5 text-slate-300","children":"Introduction to Amplia Therapeutics Limited"}]]}]]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Quarterly Activities/Appendix 4C Cash Flow Report"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"29 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Quarterly Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"ATX, a commitments test entity on ASX, reports positive cash flow from operating activities for the quarter ending with $2.5 million in Appendix 4C of their financial statements, indicating strong operational liquidity and potential reinvestment or dividend opportunities for investors"}]]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Change in substantial holding"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"22 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Substantial Holder"}]]}],""]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Narmafotinib Large-Scale Manufacture Complete"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"21 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Progress Report"}]]}],""]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does ATX do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does ATX do?"}],["$","p",null,{"className":"text-slate-400","children":"Amplia Therapeutics Limited is an Australian clinical-stage biotechnology company focused on developing small molecule inhibitors for Focal Adhesion Kinase (FAK) and p38 MAPK. Their primary drug candidates, AMP945 and AMP880, are being investigated for the treatment of various cancers (like pancreatic cancer) and fibrotic diseases (such as idiopathic pulmonary fibrosis)."}]]}],["$","div","Is ATX a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is ATX a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"Investing in ATX is highly speculative, characteristic of micro-cap biotechnology companies on the ASX. Its potential for significant returns is directly linked to successful clinical trial outcomes and eventual commercialisation of its drug candidates, but it carries substantial risks, including trial failures, funding challenges, and intense competitive pressures in the biopharmaceutical sector."}]]}],["$","div","What drives ATX's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives ATX's share price?"}],["$","p",null,{"className":"text-slate-400","children":"The share price of ATX is primarily driven by announcements related to its clinical trial progress, particularly positive or negative data readouts for AMP945 and AMP880, regulatory milestones (e.g., approvals for trial progression), securing new funding, and potential partnership or licensing agreements with larger pharmaceutical companies."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.12"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["71.4","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$64M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"23/12/2013"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","180.50"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL Ltd is a global biopharmaceutical company specialising in the development, manufacture, and marketing of plasma-derived therapies, vaccines, and recombinant technologies. It holds a dominant market position in critical areas such as immunology, haematology, and influenza prevention through its CSL Behring and Seqirus businesses. The company's core operations involve a vast global plasma collection network and advanced manufacturing facilities to produce life-saving treatments."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$87.9B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.92"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-20.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$687M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.00"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-33.0","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$13M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors",{"href":"/sectors","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/ipos",{"href":"/ipos","className":"transition hover:text-white","children":"IPOs"}],["$","$L4","/compare",{"href":"/compare","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/5bd3404007bffd2a.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"ATX share price, analysis & company profile - Amplia Therapeutics Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest ATX share price overview, what Amplia Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/ATX/"}],["$","meta","5",{"property":"og:title","content":"ATX share price, analysis & company profile - Amplia Therapeutics Limited"}],["$","meta","6",{"property":"og:description","content":"Latest ATX share price overview, what Amplia Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/ATX/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"ATX share price, analysis & company profile - Amplia Therapeutics Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest ATX share price overview, what Amplia Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
